Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

The Protein Phosphatase Inhibitor Cantharidin Alters Vascular Endothelial Cell Permeability

Jörg Knapp, Peter Bokník, Iva Lüss, Sabine Huke, Bettina Linck, Hartmut Lüss, Frank U. Müller, Thorsten Müller, Peter Nacke, Thomas Noll, Hans M. Piper, Wilhelm Schmitz, Ute Vahlensieck and Joachim Neumann
Journal of Pharmacology and Experimental Therapeutics June 1999, 289 (3) 1480-1486;
Jörg Knapp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bokník
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Iva Lüss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sabine Huke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bettina Linck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hartmut Lüss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank U. Müller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thorsten Müller
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Nacke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Noll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans M. Piper
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wilhelm Schmitz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ute Vahlensieck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joachim Neumann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In this study, we characterized the effects of the protein phosphatases type 1 (PP 1) and type 2A (PP 2A) inhibitor cantharidin in endothelial cells. We identified catalytic subunits of PP 1α, PP 2Aα, and PP 2Aβ immunologically in bovine aortic endothelial cells. Moreover, we detected mRNAs coding for catalytic subunits of PP 1α, PP 1β, and PP 2Aα by hybridization with specific DNA probes in total RNA from these cells. Okadaic acid and cantharidin inhibited the activities of catalytic subunits of PP 1 (okadaic acid, 0.01–1 μM; cantharidin, 1–100 μM) and PP 2A (okadaic acid, 0.1 nM to 1 μM; cantharidin, 0.1–100 μM) separated by column chromatography in a concentration-dependent manner. Moreover, cantharidin (1 μM to 1 mM) increased the phosphorylation state of endothelial proteins including the regulatory light chains of myosin without affecting cytosolic calcium concentrations. Cantharidin (5–100 μM) increased the permeability of cultured endothelial cells in a time- and concentration-dependent manner. We suggest that inhibition of PP 1 and PP 2A activities by cantharidin increases endothelial permeability by enhancing the phosphorylation state of endothelial regulatory proteins. Thus, cantharidin might be a useful tool to study the function of protein phosphatases in endothelial barrier function.

Footnotes

  • Send reprint requests to: Dr. Jörg Knapp, Institut für Pharmakologie und Toxikologie, Westfälische Wilhelms-Universität Münster, Domagkstraβe 12, D-48129 Münster, Federal Republic of Germany. E-mail:jknapp{at}unimuenster.de

  • ↵1 This work was supported by the Deutsche Forschungsgemeinschaft and the Konferenz der Deutschen Akademien der Wissenschaften

  • Abbreviations:
    PP
    protein phosphatase
    MLC20
    regulatory light chains of myosin (20 kDa)
    MLCK
    myosin light chain kinase
    DMSO
    dimethyl sulfoxide
    PCR
    polymerase chain reaction
    • Received October 21, 1998.
    • Accepted January 22, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 289 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 289, Issue 3
1 Jun 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The Protein Phosphatase Inhibitor Cantharidin Alters Vascular Endothelial Cell Permeability
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

The Protein Phosphatase Inhibitor Cantharidin Alters Vascular Endothelial Cell Permeability

Jörg Knapp, Peter Bokník, Iva Lüss, Sabine Huke, Bettina Linck, Hartmut Lüss, Frank U. Müller, Thorsten Müller, Peter Nacke, Thomas Noll, Hans M. Piper, Wilhelm Schmitz, Ute Vahlensieck and Joachim Neumann
Journal of Pharmacology and Experimental Therapeutics June 1, 1999, 289 (3) 1480-1486;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

The Protein Phosphatase Inhibitor Cantharidin Alters Vascular Endothelial Cell Permeability

Jörg Knapp, Peter Bokník, Iva Lüss, Sabine Huke, Bettina Linck, Hartmut Lüss, Frank U. Müller, Thorsten Müller, Peter Nacke, Thomas Noll, Hans M. Piper, Wilhelm Schmitz, Ute Vahlensieck and Joachim Neumann
Journal of Pharmacology and Experimental Therapeutics June 1, 1999, 289 (3) 1480-1486;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Evidence That Melanocortin 4 Receptor Mediates Hemorrhagic Shock Reversal Caused by Melanocortin Peptides
  • Effects of Antidepressants and Benzodiazepine-Type Anxiolytic Agents on Hepatic Porphyrin Accumulation in Primary Cultures of Chick Embryo Liver Cells
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics